Drug
Bardoxolone Methyl
Bardoxolone Methyl: highest development phase Phase 3, developed by Biogen. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Bardoxolone methyl NCT03068130 | Phase 3 | Pulmonary Hypertension |
| Bardoxolone Methyl 20 mg NCT01576887 | Phase 2 | End-Stage Renal Disease |
| Bardoxolone methyl NCT02036970 | Phase 2 | Pulmonary Arterial Hypertension |
Latest
No recent events.
Follow Bardoxolone Methyl on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.